Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Cesca Therapeutics I (KOOL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 29,670
  • Shares Outstanding, K 9,790
  • Annual Sales, $ 11,930 K
  • Annual Income, $ -18,590 K
  • 36-Month Beta -0.37
  • Price/Sales 2.61
  • Price/Book 0.86

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.62 +19.47%
on 11/11/16
3.70 -15.41%
on 11/18/16
+0.36 (+13.00%)
since 11/09/16
3-Month
2.62 +19.47%
on 11/11/16
4.60 -31.96%
on 10/24/16
-0.93 (-22.91%)
since 09/09/16
52-Week
1.60 +95.63%
on 01/20/16
7.80 -59.87%
on 12/11/15
-4.47 (-58.82%)
since 12/09/15

Most Recent Stories

More News
Cesca Therapeutics to Present at the 9th Annual LD Micro Main Event

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today announced that it is scheduled to present at the 9th...

Cesca Therapeutics Reports First Quarter Fiscal 2017 Results and Provides Business Update

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, today reported first quarter financial results for 2017 and...

Cesca Therapeutics to Announce First Quarter Fiscal 2017 Results on November 17, 2016

Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cellular processing and point-of-care autologous cell-based therapeutics, announced today it will report financial results for the fiscal...

Boyalife Announces Recent Changes to Management and the Board of Directors of Cesca Therapeutics by Majority Shareholder Vote

Boyalife Investment Inc. and Boyalife (Hong Kong) Limited (collectively, "Boyalife"), as the majority shareholders of Cesca Therapeutics Inc. (NASDAQ: KOOL) (the "Company), an autologous...

Cesca Therapeutics Granted Third U.S. Patent Relating to Its Proprietary SurgWerks(TM) Platform

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the third...

Cesca Therapeutics to Present & Exhibit at the ISCT North America 2016 Regional Meeting

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Dalip Sethi, Ph.D., Director of Clinical Research, will be presenting at the 2016 International...

Cesca Therapeutics Reports Fourth Quarter and Fiscal 2016 Year End Results

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported fourth quarter and full year financial results for fiscal 2016 and provided an update to investors....

Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first...

Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal fourth quarter and full year ended June...

Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw(R) Global Investment Conference

Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Michael Bruch, Cesca's Chief Financial Officer, and Dalip Sethi, Ph.D., Director of Clinical...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Cesca Therapeutics Inc. is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It also develops and manufactures automated blood and bone marrow processing systems and companion disposable products that enable the separation,...

See More

Support & Resistance

2nd Resistance Point 3.28
1st Resistance Point 3.20
Last Price 3.13
1st Support Level 3.00
2nd Support Level 2.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.